Deals and Financings

• Shanghai Hansoh Pharma acquired Greater China rights to a therapy for endometriosis and uterine fibroids from Korea’s TiumBio in a $170 million deal;
• Insilico Medicine, a Hong Kong-based AI drug discovery company, closed a $35 million D2 round led by Aramco Ventures’ growth fund that will expand Insilico’s AI focus into new areas;
• Shanghai Epigenic Therapeutics raised $20 million in Angel and Pre-A fundings to develop new therapies using gene editing technology that regulates the epigenetic genome;
• Singapore’s Axcynsis Therapeutics, an ADC company formed six months ago, established an R&D center in Shanghai and raised $15 million in seed financing;

Trials and Approvals

• LianBio (Nasdaq: LIAN) completed enrollment in a China Phase III trial of mavacamten in patients with obstructive hypertrophic cardiomyopathy;
• Boston’s EQRx started a US Phase III trial of its in-licensed EGFR therapy for lung cancer patients, which EQRx acquired from China’s Hansoh;
• Nanjing Frontier Biotech announced positive results from a Phase I trial of its COVID-19 therapy, a small molecule inhibitor of coronavirus main protease;
• Arbele, a US-China immunotherapy company, dosed the first patient in an Australian Phase I trial of a bispecific for patients with advanced gastrointestinal cancers;
• Inmagene Biopharma and HutchMed (Nasdaq:HCM) started a global Phase I trial of their partnered BTK inhibitor for immunological diseases;
• Shenzhen ImmVira reported its oncolytic herpes simplex virus product was granted Orphan Drug Designation in the US to treat malignant glioma.

More By This Author:

Week In Review: Innovent Lands $305 Million Investment From Sanofi; Will Partner Two Candidates In China
Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking
Week In Review: WuXi Biologics And WuXi AppTec Plan $2.8 Billion Investment In Singapore Facilities